News for Axsome Therapeutics, Inc. (AXSM)

Recent Transaction Overview On February 28, 2025, SVB Capital Management, LLC (Trades, Portfolio) executed a significant transaction involving Root Inc (ROOT),

On March 5, 2025, Axsome Therapeutics Inc (AXSM), a leader in biopharmaceutical innovations for central nervous system disorders, announced a settlement agreeme

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of cen

Axsome Therapeutics said that in the FDA meeting meetings, the agency has supported a supplemental NDA submission for AXS-05 in Alzheimer’s disease agitation.

Axsome Therapeutics Inc (AXSM), a leader in biopharmaceutical innovations for central nervous system disorders, announced on March 3, 2025, that it has received

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM), a

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc.

Summary Axsome Therapeutics Inc (AXSM), a leading biopharmaceutical company focused on central nervous system (CNS) disorders, announced its participation in tw

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (

Axsome Therapeutics Inc (AXSM), a leader in CNS disorder treatments, announced on February 24, 2025, that its Phase 3 EMERGE trial demonstrated the efficacy of

SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p<0.001, mTOQ-4 t

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc.

Axsome Therapeutics Inc (AXSM), a leader in the treatment of central nervous system (CNS) disorders, announced its financial results for the fourth quarter and

Total Product Revenue: $118.8 million for Q4 2024; $385.7 million for full year 2024, representing 66% and 88% year-over-year growth, respectively.Auvelity Net

Feb 18, 2025 / 01:00PM GMTOperator Good morning, and welcome to the Axsome Therapeutics' fourth quarter and full year 2024 conference call. Currently, all parti

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key launches...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ETCompany ParticipantsDarren Opland - Director, Corporate...

The following slide deck was published by Axsome Therapeutics, Inc.